TD Cowen downgraded Harpoon Therapeutics (HARP) to Market Perform from Outperform without a price target following the proposed acquisition by Merck (MRK) for $23 per share in cash. The analyst believes another party is unlikely to offer a higher price, and that the transaction should close in the first half of 2024.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on HARP:
- Biotech Alert: Searches spiking for these stocks today
- Oppenheimer raises Harpoon target, wonders if Merck deal could be starting point
- Harpoon Therapeutics downgraded to Hold from Buy at Canaccord
- Harpoon Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
- M & A News: Merck (NYSE:MRK) to Acquire Harpoon for $680 Million